ALK and non-small cell lung carcinoma: Alectinib and ceritinib demonstrated significant survival benefits for previously untreated advanced ALK-rearranged NSCLC patients (9) Ceritinib and alectinib were approved for use as the second-line and third-line therapy in this patient, but the disease still progressed.